Jan Peter Yska1, Douwe H van der Meer2, Albert R Dreijer2, Willeke Eilander2, Jan A Apers3, Marloes Emous3, Erik R E Totté3, Bob Wilffert4,5, Eric N van Roon2,4. 1. Department of Clinical Pharmacy and Clinical Pharmacology, Medical Centre Leeuwarden, PO Box 888, 8901 BR, Leeuwarden, The Netherlands. j.p.yska@znb.nl. 2. Department of Clinical Pharmacy and Clinical Pharmacology, Medical Centre Leeuwarden, PO Box 888, 8901 BR, Leeuwarden, The Netherlands. 3. Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, The Netherlands. 4. Unit of Pharmacotherapy and Pharmaceutical Care, Department of Pharmacy, University of Groningen, Groningen, The Netherlands. 5. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
PURPOSE: Bariatric surgery can influence the prevalence and incidence of comorbidities, as well as the pharmacokinetics of drugs. This might lead to changes in the use of drugs. This study aimed to assess the influence of bariatric surgery on the use of medication in patients before and after surgery, focusing on type, number of medications, and daily dosage. METHODS: In a retrospective and prospective observational study, drug dispensing data from pharmacies of patients undergoing their first bariatric surgery between January 2008 and September 2011 was collected. Dispensing data from 1 month before until 12 months after surgery was analyzed. Drugs were classified according to the WHO-ATC classification system. Dosages of drugs were compared using defined daily dose (DDD). RESULTS: Among 450 patients, 12 months after surgery, the mean number of drugs per patient for antidiabetics, drugs acting on the cardiovascular system, anti-inflammatory and antirheumatic drugs, and drugs for obstructed airway diseases decreased by, respectively, 71.3 % (95 % CI 57.2 to 85.4), 34.5 % (95 % CI 28.2 to 43.0), 45.5 % (95 % CI 13.3 to 72.6), and 33.1 % (95 % CI 15.3 to 53.2). Patients used lower median DDD of oral antidiabetics, beta-blocking agents, and lipid-modifying drugs. CONCLUSIONS: For some major drug classes 12 months after bariatric surgery, the use of drugs decreases in terms of mean number per patient. A reduction in dose intensity was observed for oral antidiabetics, beta-blocking agents, and lipid-modifying drugs. Dispensing data from pharmacies may provide detailed information on the use of medications by patients after bariatric surgery.
PURPOSE: Bariatric surgery can influence the prevalence and incidence of comorbidities, as well as the pharmacokinetics of drugs. This might lead to changes in the use of drugs. This study aimed to assess the influence of bariatric surgery on the use of medication in patients before and after surgery, focusing on type, number of medications, and daily dosage. METHODS: In a retrospective and prospective observational study, drug dispensing data from pharmacies of patients undergoing their first bariatric surgery between January 2008 and September 2011 was collected. Dispensing data from 1 month before until 12 months after surgery was analyzed. Drugs were classified according to the WHO-ATC classification system. Dosages of drugs were compared using defined daily dose (DDD). RESULTS: Among 450 patients, 12 months after surgery, the mean number of drugs per patient for antidiabetics, drugs acting on the cardiovascular system, anti-inflammatory and antirheumatic drugs, and drugs for obstructed airway diseases decreased by, respectively, 71.3 % (95 % CI 57.2 to 85.4), 34.5 % (95 % CI 28.2 to 43.0), 45.5 % (95 % CI 13.3 to 72.6), and 33.1 % (95 % CI 15.3 to 53.2). Patients used lower median DDD of oral antidiabetics, beta-blocking agents, and lipid-modifying drugs. CONCLUSIONS: For some major drug classes 12 months after bariatric surgery, the use of drugs decreases in terms of mean number per patient. A reduction in dose intensity was observed for oral antidiabetics, beta-blocking agents, and lipid-modifying drugs. Dispensing data from pharmacies may provide detailed information on the use of medications by patients after bariatric surgery.
Entities:
Keywords:
Bariatric surgery; Defined daily dose; Dispensing data; Medication use
Authors: Jan Peter Yska; Susanne van der Linde; Véronique V Tapper; Jan A Apers; Marloes Emous; Erik R Totté; Bob Wilffert; Eric N van Roon Journal: Obes Surg Date: 2013-06 Impact factor: 4.129
Authors: Jan Peter Yska; Eric N van Roon; Anthonius de Boer; Hubert G M Leufkens; Bob Wilffert; Loek J M de Heide; Frank de Vries; Arief Lalmohamed Journal: JAMA Surg Date: 2015-12 Impact factor: 14.766
Authors: Matthew L Maciejewski; Edward H Livingston; Leila C Kahwati; William G Henderson; Andrew L Kavee; David E Arterburn Journal: Surg Obes Relat Dis Date: 2010-07-29 Impact factor: 4.734
Authors: Jodi B Segal; Jeanne M Clark; Andrew D Shore; Francesca Dominici; Thomas Magnuson; Thomas M Richards; Jonathan P Weiner; Eric B Bass; Albert W Wu; Martin A Makary Journal: Obes Surg Date: 2009-12 Impact factor: 4.129
Authors: Viktoria L Gloy; Matthias Briel; Deepak L Bhatt; Sangeeta R Kashyap; Philip R Schauer; Geltrude Mingrone; Heiner C Bucher; Alain J Nordmann Journal: BMJ Date: 2013-10-22
Authors: Jan Peter Yska; Sanneke Gertsen; Gerbrich Flapper; Marloes Emous; Bob Wilffert; Eric N van Roon Journal: Obes Surg Date: 2016-12 Impact factor: 4.129
Authors: Jan Peter Yska; Jacquelien T M Wanders; Blessing Odigie; Jan A Apers; Marloes Emous; Erik R E Totté; E Christiaan Boerma; Froukje L Ubels; Herman J Woerdenbag; Henderik W Frijlink; Bob Wilffert; Eric N van Roon Journal: Eur J Hosp Pharm Date: 2019-02-15
Authors: Jan Peter Yska; Ronald J Punter; Herman J Woerdenbag; Marloes Emous; Henderik W Frijlink; Bob Wilffert; Eric N van Roon Journal: Eur J Hosp Pharm Date: 2018-02-08
Authors: Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe Journal: Br J Clin Pharmacol Date: 2021-06-03 Impact factor: 3.716